Can patients with intestinal cancer take pazopanib (Vita) and analysis of its efficacy

Pazopanib is an oral multi-target tyrosine kinase inhibitor that mainly acts on VEGFR, PDGFR and c-Kit signaling pathways, thereby inhibiting tumor angiogenesis and tumor growth. It is approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. Pazopanib has not yet been approved as a standard first- or second-line treatment in patients with bowel cancer (colorectal cancer), but it has shown potential as an exploratory treatment for refractory or metastatic bowel cancer in some clinical studies and real-world applications.

In terms of efficacy, pazopanib indirectly inhibits tumor growth mainly by inhibiting tumor angiogenesis. Some early clinical trials have shown that for patients with advanced bowel cancer who have failed multiple lines of chemotherapy, pazopanib alone or in combination with chemotherapy can delay disease progression to a certain extent and improve the progression-free survival of some patients (PFS). Although the overall response rate (ORR) is limited, cases of tumor volume reduction and disease stabilization have been observed in some angiogenesis-dependent tumor lesions, providing new treatment ideas for refractory patients.

In actual clinical application, the tolerability of pazopanib in patients with bowel cancer needs to be closely monitored. Common side effects include high blood pressure, abnormal liver function, fatigue, diarrhea, and hand-foot syndrome. Patients need to regularly monitor liver and kidney function and blood pressure during use in order to adjust the dosage and deal with adverse reactions in a timely manner. Patients with other medications or underlying diseases should carefully evaluate potential drug interactions and risks to ensure medication safety.

Overall, pazopanib can be considered as an exploratory or individualized treatment option under the guidance of clinicians when patients with bowel cancer are ineffective with standard treatments or cannot tolerate conventional regimens. Although the efficacy is limited, it can delay disease progression and improve quality of life in some patients. Clinicians need to comprehensively assess risks and benefits based on tumor molecular characteristics, previous treatment history, and patient tolerance, and formulate individualized medication plans.

Reference link:https://www.drugs.com